Skip to main content

Table 1 Baseline demographic and comorbidity characteristics by medication status of new bisphosphonate users at the end of 12 months follow up

From: Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries

Medication status of new bisphosphonate users at the end of 12 months follow up
  Continued original bisphosphonate use Discontinued without switching or restarting Restarted the same bisphosphonates after a treatment gap Switched to another anti-osteoporosis medication
N 9,510 7,827 1,819 2,296
Age, years (SD) 78 (6.8) 78 (6.8) 78 (6.7) 78 (6.8)
Median Household Income, $ (SD) 46,318 (22,808) 44,415 (22,715) 45,015 (23,123) 45,142 (22,540)
Sex     
Female 8,562 (90.3) 6,965 (89.0) 1,639 (90.1) 2,104 (91.6)
Male 948 (10.0) 862 (11.0) 180 (9.9) 192 (8.4)
Race/ethnicity     
Black 455 (4.8) 455 (5.8) 125 (6.9) 94 (4.1)
White 8,194 (86.2) 6,486 (82.9) 1,456 (80.0)* 1,920 (83.6)
Asian 360 (3.8) 319 (4.1) 92 (5.1) 130 (5.7)
Hispanic 285 (3.0) 382 (4.9) 95 (5.2) 107 (4.7)
Other 216 (2.3) 185 (2.4) 51 (2.8) 45 (2.0)
Geographic region     
Northeast 1,717 (18.1) 1,340 (17.1) 355 (19.5) 382 (16.6)
Midwest 2,534 (26.6) 1,805 (23.1) 417 (22.9) 568 (24.7)
South 3,540 (37.2) 3,287 (42.0) 701 (38.5) 903 (39.3)
West 1,719 (18.1) 1,395 (17.8) 346 (19.0) 443 (19.3)
Charlson score     
0 3,945 (41.5) 3,007 (38.4) 712 (39.1) 937 (40.8)
1-3 3,831 (40.3) 3,222 (42.2) 783 (43.0) 931 (40.5)
> 3 1,734 (18.2) 1,598 (20.4) 324 (17.8) 428 (18.6)
Hospitalizations 2,350 (24,7) 1,961 (25.1) 448 (24.6) 623 (27.1)*
In long-term care 1,146 (12.1)* 659 (8.4) 156 (8.6) 303 (13.2)
History of any fractures 1,051 (11.1) 704 (9.0) 162 (8.9) 272 (11.8)
History of DXA 5,641 (59.3)* 4,154 (53.1) 883 (48.5) 1,328 (57.8)
Dual Eligible 2,807 (29.5) 2,624 (33.5) 650 (35.7) 779 (33.9)
Eligible for low income subsidy 3,011 (31.7) 2,877 (36.8) 690 (37.9) 841 (36.6)
Entered Medicare part D coverage gap 1,826 (19.2) 1,613 (20.6) 367 (20.2) 471 (20.5)
Proton pump inhibitors 2,430 (25.6) 2,070 (26.5) 517 (28.4) 709 (30.9)
Doctor visit type     
Internal Medicine visits 6,220 (65.4) 5,085 (65.0) 1,170 (64.3) 1,564 (68.1)
Family Practice visits 4,446 (46.8) 3,654 (46.7) 781 (42.9) 1,107 (48.2)
Medical Oncology visits 940 (9.9) 721 (9.2) 159 (8.7) 222 (9.7)
Rheumatology/Endo visits 1,706 (17.9) 1,150 (14.7) 304 (16.7) 430 (18.7)*
Number of Physician Visits     
0-5 2,978 (31.3) 2,305 (29.4) 571 (31.4) 579 (25.2)
6-10 2,516 (26.5) 2,018 (25.8) 462 (25.4) 578 (25.2)
11-15 1,665 (17.5) 1,379 (17.6) 307 (16.9) 438 (19.1)
> 15 2,351 (24.7) 2,125 (27.1) 479 (26.3) 701 (30.5)
  1. Numbers in table are n (column percent) or mean (standard deviation).
  2. *Standardized difference score between current column and continued original bisphosphonate use column is greater than 0.1.